5 Einträge gefunden

1. High-risk additional chromosomal abnormalities at low blast counts herald death by CML

   1. Hehlmann, Rüdiger
   2. Voskanyan, Astghik
   3. Lauseker, Michael
   4. Pfirrmann, Markus
   5. Kalmanti, Lida
   6. Rinaldetti, Sebastien
   7. Kohlbrenner, Katharina

   2020 - Forschungsinformationssystem des UKE
2. Correction: High-risk additional chromosomal abnormalities at low blast counts herald death by CML

   1. Hehlmann, Rüdiger
   2. Voskanyan, Astghik
   3. Lauseker, Michael
   4. Pfirrmann, Markus
   5. Kalmanti, Lida
   6. Rinaldetti, Sebastien
   7. Kohlbrenner, Katharina

   2020 - Forschungsinformationssystem des UKE
3. Clonal Evolution and Blast Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2 Fusion Type CML under Imatinib Therapy

   1. Haaß, Wiltrud
   2. Kleiner, Helga
   3. Weiß, Christel
   4. Haferlach, Claudia
   5. Schlegelberger, Brigitte
   6. Müller, Martin C
   7. Hehlmann, Rüdiger

   2015 - Forschungsinformationssystem des UKE - frei zugänglich
4. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV

   1. Hehlmann, Rüdiger
   2. Müller, Martin C
   3. Lauseker, Michael
   4. Hanfstein, Benjamin
   5. Fabarius, Alice
   6. Schreiber, Annette
   7. Proetel, Ulrike

   2014 - Forschungsinformationssystem des UKE
5. Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia.

   1. Hehlmann, Rüdiger
   2. Lauseker, Michael
   3. Jung-Munkwitz, Susanne
   4. Leitner, Armin
   5. Müller, Martin C
   6. Pletsch, Nadine
   7. Proetel, Ulrike

   2011 - Forschungsinformationssystem des UKE